Insomnia Pipeline Products and Comparative Analysis with Company Profiles Research Report Available at RnRMarketResearch.com
Dallas, Texas (PRWEB) July 15, 2015 -- This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects.
Complete report with TOC is available at http://www.rnrmarketresearch.com/insomnia-pipeline-review-h1-2015-market-report.html.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this report are:
• Actelion Ltd
• Alexza Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Evotec AG
• Grupo Ferrer Internacional, S.A.
• Heptares Therapeutics Ltd.
• Intec Pharma ltd.
• Intra-Cellular Therapies, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Minerva Neurosciences, Inc.
• Neurim Pharmaceuticals Ltd
• Novartis AG
• Reviva Pharmaceuticals Inc.
• Rottapharm SpA
• Shionogi & Co., Ltd.
• Somnus Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited
Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=395214. (This is a premium report priced at US$2000 for a single user License.)
Drug profiles mentioned in this reports are:
• ACT-462206
• CR-5542 Series
• Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia
• EVT-201
• ITI-007
• JNJ-42847922
• LASSBio-785
• LASSBio-786
• lemborexant
• lorediplon
• MIN-202
• MK-8133
• piromelatine
• ramelteon
• RP-15000
• S-117957
• Small Molecule to Antagonize Orexin 1 and 2 Receptors for Insomnia
• Small Molecule to Inhibit OX2R for Insomnia
• UCM-765
• zaleplon
• zaleplon DR
• zaleplon GR
• zolpidem tartrate
Scope of this report:
The report provides a snapshot of the global therapeutic landscape of Insomnia. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects. Coverage of the Insomnia pipeline on the basis of target, MoA, route of administration and molecule type. Latest news and deals relating related to pipeline products.
Table of Contents:
• List of Tables
• List of Figures
• Insomnia Overview
• Therapeutics Development
• Pipeline Products for Insomnia - Comparative Analysis
• Insomnia - Therapeutics under Development by Companies
• Insomnia - Therapeutics under Investigation by Universities/Institutes
• Insomnia - Pipeline Products Glance
• Late Stage Products
• Clinical Stage Products
• Early Stage Products
• Drug Profiles
• Featured News & Press Releases
Ritesh Tiwari
TX, Dallas North - Dominion Plaza
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales(at)rnrmarketresaerch(dot)com
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article